SSX2 anticorps

N° du produit ABIN2461583

Détail du produit anti-SSX2 anticorps

Antigène: SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SSX2 est non-conjugé

Application: Western Blotting (WB), ELISA

Purification: Antibody is purified by peptide affinity chromatography method.

Immunogène: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human SSX2.

Information d'application

Indications d'application: SSX2 antibody can be used for detection of SSX2 by ELISA at 1:62500. SSX2 antibody can be used for detection of SSX2 by western blot at 1.25 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 - 100,000.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Add 50 ?L of distilled water. Final antibody concentration is 1 mg/mL.

Concentration: 1 mg/mL

Buffer: Antibody is lyophilized in PBS buffer with 2 % sucrose.

Conseil sur la manipulation: As with any antibody avoid repeat freeze-thaw cycles.

Stock: 4 °C/-20 °C

Stockage commentaire: For short periods of storage (days) store at 4 °C. For longer periods of storage, store SSX2 antibody at -20 °C.

Détails sur SSX2

Antigène: SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Autre désignation: SSX2 (SSX2 Produits)

Synonymes: anticorps CT5.2, anticorps CT5.2A, anticorps HD21, anticorps HOM-MEL-40, anticorps SSX, anticorps SSX2, anticorps SSX3, anticorps SSX family member 2, anticorps protein SSX2, anticorps synovial sarcoma, X breakpoint 2, anticorps SSX2, anticorps LOC741661, anticorps Ssx2

Sujet: SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t (X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t (X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.

Poids moléculaire: 25 kDa

ID gène: 6757

NCBI Accession: NP_003138